Product Licensing

Primagen expands into cardiovascular field with CD133 diagnostic biomarker technology license

Published in Blood Weekly, May 25th, 2006

Primagen Holding BV announced that the exclusive, worldwide license for the CD133 diagnostic biomarker has been expanded to include the cardiovascular field. Primagen originally licensed the CD133 biomarker from The University of Texas M. D. Anderson Cancer Center.

CD133 is a genetic expression marker for presence of developing endothelial cells in the peripheral blood circulation and is associated with angiogenesis, the growth of new capillary blood vessels. Clinical research from several academic centers in Europe and the U.S. has shown that CD133 is a promising prognostic indicator of tumor growth.

"New research suggests that the CD133 biomarker...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-05-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry